Article

Protein predicts post-RP cancer recurrence, death

Men who had high levels of the activated Stat5 protein in their prostate cancer after a radical prostatectomy were more likely to have a recurrence or die from the disease compared to men who had little to no presence of the growth protein, according to a recent report.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
Related Content
Katie S. Murray, DO, MS
June 18th 2025

Clinical Forum: Advances in low-grade UTUC treatment and care

Urology Times staff
The conversation touched on risk stratification, which plays a central role in deciding among surgical options.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
FDA approves integrated sacral neuromodulation system for urinary urge incontinence
June 18th 2025

FDA approves integrated sacral neuromodulation system for urinary urge incontinence

Hannah Clarke
The approval is supported by landmark results from the pivotal phase 2 SANS-UUI trial.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke
ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
June 17th 2025

FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

Hannah Clarke
Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
© 2025 MJH Life Sciences

All rights reserved.